These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35084903)

  • 1. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.
    Borodovsky JT; Sofis MJ; Sherman BJ; Gray KM; Budney AJ
    Psychol Addict Behav; 2022 Aug; 36(5):515-525. PubMed ID: 35084903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.
    Sherman BJ; Sofis MJ; Borodovsky JT; Gray KM; McRae-Clark AL; Budney AJ
    Psychol Addict Behav; 2022 Aug; 36(5):505-514. PubMed ID: 34197135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial.
    Tomko RL; Baker NL; McClure EA; Sonne SC; McRae-Clark AL; Sherman BJ; Gray KM
    Drug Alcohol Depend; 2018 Jan; 182():1-7. PubMed ID: 29112827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.
    Lee DC; Schlienz NJ; Peters EN; Dworkin RH; Turk DC; Strain EC; Vandrey R
    Drug Alcohol Depend; 2019 Jan; 194():500-517. PubMed ID: 30530238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
    Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
    Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis Use in Adults Who Screen Positive for Attention Deficit/Hyperactivity Disorder: CANreduce 2.0 Randomized Controlled Trial Subgroup Analysis.
    Ahlers J; Baumgartner C; Augsburger M; Wenger A; Malischnig D; Boumparis N; Berger T; Stark L; Ebert DD; Haug S; Schaub MP
    J Med Internet Res; 2022 Apr; 24(4):e30138. PubMed ID: 35442196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Web-Based Self-Help Intervention With and Without Chat Counseling to Reduce Cannabis Use in Problematic Cannabis Users: Three-Arm Randomized Controlled Trial.
    Schaub MP; Wenger A; Berg O; Beck T; Stark L; Buehler E; Haug S
    J Med Internet Res; 2015 Oct; 17(10):e232. PubMed ID: 26462848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.
    Loflin MJE; Kiluk BD; Huestis MA; Aklin WM; Budney AJ; Carroll KM; D'Souza DC; Dworkin RH; Gray KM; Hasin DS; Lee DC; Le Foll B; Levin FR; Lile JA; Mason BJ; McRae-Clark AL; Montoya I; Peters EN; Ramey T; Turk DC; Vandrey R; Weiss RD; Strain EC
    Drug Alcohol Depend; 2020 Jul; 212():107993. PubMed ID: 32360455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal dynamics of the relationship between change in depressive symptoms and cannabis use in adolescents receiving psychosocial treatment for cannabis use disorder.
    Arias AJ; Hammond CJ; Burleson JA; Kaminer Y; Feinn R; Curry JF; Dennis ML
    J Subst Abuse Treat; 2020 Oct; 117():108087. PubMed ID: 32811625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
    Rømer Thomsen K; Thylstrup B; Kenyon EA; Lees R; Baandrup L; Feldstein Ewing SW; Freeman TP
    Neurosci Biobehav Rev; 2022 Jan; 132():169-180. PubMed ID: 34822876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated cognitive-behavioral therapy for comorbid cannabis use and anxiety disorders: The impact of severity of cannabis use.
    Buckner JD; Morris PE; Zvolensky MJ
    Exp Clin Psychopharmacol; 2021 Jun; 29(3):272-278. PubMed ID: 34264732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
    Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N
    Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.
    Baker NL; Gray KM; Sherman BJ; Morella K; Sahlem GL; Wagner AM; McRae-Clark AL
    Drug Alcohol Depend; 2018 Jun; 187():270-277. PubMed ID: 29698894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users.
    Taylor M; Lees R; Henderson G; Lingford-Hughes A; Macleod J; Sullivan J; Hickman M
    Drug Alcohol Rev; 2017 Mar; 36(2):220-226. PubMed ID: 27296783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When and How to Treat Possible Cannabis Use Disorder.
    Lévesque A; Le Foll B
    Med Clin North Am; 2018 Jul; 102(4):667-681. PubMed ID: 29933822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
    Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR
    Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mediating roles of coping, sleep, and anxiety motives in cannabis use and problems among returning veterans with PTSD and MDD.
    Metrik J; Jackson K; Bassett SS; Zvolensky MJ; Seal K; Borsari B
    Psychol Addict Behav; 2016 Nov; 30(7):743-754. PubMed ID: 27786514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported symptoms of cannabis use disorder: Psychometric testing and validation.
    Richards DK; Schwebel FJ; Sotelo M; Pearson MR;
    Exp Clin Psychopharmacol; 2021 Apr; 29(2):157-165. PubMed ID: 34043399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who responds best to text-delivered cannabis use disorder treatment? A randomized clinical trial with young adults.
    Mason MJ; Zaharakis NM; Moore M; Brown A; Garcia C; Seibers A; Stephens C
    Psychol Addict Behav; 2018 Nov; 32(7):699-709. PubMed ID: 30265057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.